Johnson & Johnson (NYSE: JNJ) has made headlines with its decision to acquire V-Wave Ltd., a private company renowned for its cutting-edge treatments for heart failure. The agreement, valued at an upfront payment of $600 million and potential additional payments totaling approximately $1.1 billion, marks a strategic expansion for Johnson & Johnson MedTech. This acquisition […]
Bayer AG and its subsidiary Asklepios BioPharmaceutical, Inc. (AskBio), have achieved a significant milestone in the fight against congestive heart failure (CHF) with the randomization of the first patient in the Phase II GenePHIT trial for AB-1002 (NAN-101). This trial represents a critical step forward in the development of new treatments for CHF, a condition […]
Zydus Lifesciences Limited, a significant player in the pharmaceutical industry, has received final approval from the United States Food and Drug Administration (FDA) for its Ivabradine Tablets, available in 5 mg and 7.5 mg dosages. This approval marks a critical step for Zydus in the heart failure medication market. Ivabradine Tablets’ Indications and Market Potential […]
WhiteSwell, a frontrunner in the treatment of acute decompensated heart failure (ADHF), has shared optimistic initial results from its continuing DELTA-HF trial centered around the WhiteSwell eLym System. Unveiled at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio, the eLym System emerges as a minimally invasive catheter-based system that […]
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF). Despite a numerical improvement in certain outcomes, the study failed to achieve statistical significance for […]
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic chronic heart failure (HF). This follows an earlier authorization for patients suffering from heart failure with reduced ejection fraction (HFrEF). Now, Forxiga’s capabilities extend to all adults with symptomatic chronic […]
Indian cardiac digital therapeutics entity, Lupin Digital Health (LDH), marked another achievement with the unveiling of its Lyfe Digital Heart Failure Clinic. Designed to cater to the escalating 10 million-plus heart failure patients in India, this avant-garde e-clinic blends the convenience of home-based care with the precision of in-clinic consultations. Addressing India’s Cardiac Health Concerns […]
BaroPace Inc., a medical technology company focused on developing pacemaker regulation techniques based on blood pressure, has been granted approval by the Central Drugs Standard Control Organisation (CDSCO) of India to carry out its clinical trial, RelieveHFpEF-II, in the country. The RelieveHFpEF-II trial is a randomized, cross-over design, First-in-Human, Early Feasibility Study that employs BaroPace’s […]
Viz.ai, an artificial intelligence (AI) powered health technology company, has signed a multi-year agreement with Bristol Myers Squibb (BMY) to provide the latter with an AI algorithm and provider workflow software called Viz HCM. The AI algorithm and the Viz HCM software are intended to be used by Bristol Myers Squibb for identifying and triaging […]
Glenmark Pharmaceuticals said that it has rolled out the sacubitril + valsartan tablets for the treatment of heart failure in India under the brand name Sacu V. According to Glenmark Pharmaceuticals, Sacu V should be taken daily two times under doctor’s prescription. The approved indication of sacubitril + valsartan tablets is for reduction of the […]